…
Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotopically pure radiochemicals for medical, industrial, and research applications. The Cobalt Products segment produces cobalt-60 products and services, the fabrication of cobalt-60 sealed sources for radiation therapy, industrial and medical applications, and recycling of expended cobalt-60 sources. The Calibration & Reference Products segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. This segment also offers flood sources, dose calibrators, cylinder phantoms, rod sources, line sources, flexible and rigid rulers, spot markers, pen point markers, and various specialty design items. The Medical Devices segment develops EasyFill Automated Capsule System, a robotic lab device. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. The company sells its products directly to end users and distributors. The company was formerly known as International Isotopes Inc. and changed its name to Radnostix, Inc. in December 2025. Radnostix, Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
International Isotopes Inc. develops and supplies medical and specialty isotopes and related services for diagnostic, therapeutic and industrial applications and appears positioned in the nuclear medicine supply chain. Long-term growth drivers may include rising demand for diagnostic and therapeutic isotopes, recurring supply shortages that could support additional producers, and possible capacity expansion initiatives. Investors may find exposure to a specialized, regulated niche with structural demand pressure appealing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -0.91M | 0.01M | -0.87M | 0.30M | -0.79M |
| Minority interest | - | - | - | 0.00M | -0.11M |
| Net income | -0.91M | 0.01M | -0.87M | 0.30M | -0.90M |
| Selling general administrative | 8.22M | 8.03M | 7.58M | 6.96M | 6.15M |
| Gross profit | 7.70M | 8.65M | 7.38M | 6.29M | 5.74M |
| Reconciled depreciation | 0.40M | 0.40M | 0.35M | 0.37M | 0.61M |
| Ebit | - | - | - | - | -0.24M |
| Ebitda | - | - | - | 1.29M | 0.61M |
| Operating income | -0.96M | 0.01M | -0.78M | -1.20M | -0.68M |
| Other operating expenses | - | - | - | - | 0.44M |
| Interest expense | 0.34M | 0.33M | 0.33M | 0.61M | 0.79M |
| Interest income | 0.08M | 0.12M | 0.08M | 0.01M | 0.00M |
| Net interest income | -0.26M | -0.21M | -0.25M | -0.60M | -0.79M |
| Total revenue | 13.07M | 13.90M | 12.27M | 11.18M | 9.66M |
| Total operating expenses | 14.03M | 13.89M | 13.04M | 12.38M | 10.34M |
| Cost of revenue | 5.37M | 5.25M | 4.89M | 4.89M | 3.92M |
| Total other income expense net | 0.31M | 0.21M | 0.16M | 2.11M | 0.68M |
| Net income from continuing ops | -0.91M | 0.01M | -0.87M | 0.30M | -0.79M |
| Net income applicable to common shares | - | - | - | - | -0.90M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 17.84M | 17.16M | 16.91M | 16.24M | 16.33M |
| Intangible assets | 3.21M | 3.37M | 3.54M | 3.70M | 3.86M |
| Other current assets | 0.64M | 0.70M | 0.67M | 1.02M | 1.00M |
| Total liab | 14.14M | 12.81M | 12.87M | 11.90M | 13.60M |
| Total stockholder equity | 3.69M | 4.35M | 4.04M | 4.34M | 2.73M |
| Deferred long term liab | - | - | - | - | 0.25M |
| Other current liab | - | - | - | - | 0.91M |
| Common stock | - | - | - | - | 5.03M |
| Capital stock | 5.28M | 5.24M | 5.20M | 5.15M | 5.03M |
| Retained earnings | -128.23M | -127.32M | -127.33M | -126.46M | -126.76M |
| Other liab | - | - | - | - | 0.89M |
| Good will | 1.38M | 1.38M | 1.38M | 1.38M | 1.38M |
| Other assets | - | - | - | - | 1.08M |
| Cash | 1.70M | 1.95M | 2.69M | 2.38M | 0.47M |
| Total current liabilities | 3.97M | 3.33M | 3.27M | 3.51M | 4.93M |
| Net debt | 0.24M | 0.26M | - | - | 1.49M |
| Short long term debt | 0.16M | 0.31M | 0.16M | 0.64M | 1.28M |
| Property plant equipment | - | - | - | - | 6.75M |
| Total current assets | 4.63M | 4.99M | 5.76M | 5.74M | 3.26M |
| Net tangible assets | - | - | - | - | -2.51M |
| Net receivables | 1.42M | 1.52M | 1.47M | 1.60M | 0.85M |
| Long term debt | 1.77M | 1.90M | 1.89M | 1.03M | 0.68M |
| Inventory | 0.88M | 0.82M | 0.93M | 0.74M | 0.92M |
| Accounts payable | 1.53M | 0.86M | 0.56M | 0.38M | 1.42M |
| Non currrent assets other | 1.49M | 1.43M | 0.88M | 0.84M | 0.83M |
| Non current assets total | 13.21M | 12.18M | 11.15M | 10.50M | 13.07M |
| Capital lease obligations | 2.91M | 2.09M | 2.24M | 2.37M | 2.50M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.69M | -0.15M | 3.88M | -0.21M |
| Change to liabilities | - | - | - | - | -0.61M |
| Total cashflows from investing activities | - | - | - | - | -0.21M |
| Net borrowings | -0.30M | -0.16M | -0.09M | - | -0.09M |
| Total cash from financing activities | -0.28M | -0.15M | -0.08M | -0.47M | -0.08M |
| Change to operating activities | - | - | - | - | 0.24M |
| Net income | -0.91M | 0.01M | -0.87M | 0.30M | -0.90M |
| Change in cash | -0.19M | -0.19M | 0.35M | 1.91M | -0.45M |
| Begin period cash flow | 3.38M | 3.57M | 3.22M | 1.31M | 1.75M |
| End period cash flow | 3.19M | 3.38M | 3.57M | 3.22M | 1.31M |
| Total cash from operating activities | 0.62M | 0.64M | 0.58M | -1.50M | -0.16M |
| Issuance of capital stock | 0.02M | 0.01M | 0.01M | 0.08M | 0.02M |
| Depreciation | 0.40M | 0.40M | 0.35M | 0.37M | 0.65M |
| Change to inventory | -0.05M | 0.11M | -0.18M | 0.18M | -0.09M |
| Change to account receivables | 0.10M | -0.05M | 0.13M | -0.74M | -0.08M |
| Other cashflows from financing activities | - | - | - | - | -0.00M |
| Change to netincome | - | - | - | - | 0.22M |
| Capital expenditures | 0.53M | 0.72M | 0.15M | 0.12M | 0.21M |
| Change in working capital | 0.92M | -0.02M | 0.59M | -1.05M | -0.53M |
| Stock based compensation | 0.12M | 0.20M | 0.46M | 0.35M | 0.08M |
| Other non cash items | 0.09M | 0.07M | 0.05M | 0.32M | 0.44M |
| Free cash flow | 0.09M | -0.08M | 0.43M | -1.62M | -0.37M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| INIS International Isotopes Inc |
- -% |
0.05 | - | 16.78 | 2.90 | 17.34 | 3.27 | 92.27 |
| MKKGY Merck KGaA ADR |
0.45 1.38% |
33.07 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
2.27 1.38% |
167.12 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.31 1.47% |
21.43 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.15 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotopically pure radiochemicals for medical, industrial, and research applications. The Cobalt Products segment produces cobalt-60 products and services, the fabrication of cobalt-60 sealed sources for radiation therapy, industrial and medical applications, and recycling of expended cobalt-60 sources. The Calibration & Reference Products segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. This segment also offers flood sources, dose calibrators, cylinder phantoms, rod sources, line sources, flexible and rigid rulers, spot markers, pen point markers, and various specialty design items. The Medical Devices segment develops EasyFill Automated Capsule System, a robotic lab device. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. The company sells its products directly to end users and distributors. The company was formerly known as International Isotopes Inc. and changed its name to Radnostix, Inc. in December 2025. Radnostix, Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.
4137 Commerce Circle, Idaho Falls, ID, United States, 83401
208 524 5300
44
| Name | Title | Year Born |
|---|---|---|
| Mr. Stephen T. Laflin | Pres, CEO & Director | 1957 |
| Mr. W. Matthew Cox B.S., CPA | CFO & Sec. | 1984 |
| Mr. Shahe Bagerdjian | President, CEO & Director | 1984 |
| Mr. W. Matthew Cox B.S., CPA | CFO & Secretary | 1984 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.